DNA Marker Identification for Kidney Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
The trial aims to identify new DNA markers in individuals with kidney tumors by collecting blood, urine, and tissue samples. These markers could enhance the diagnosis and understanding of kidney cancers. The trial seeks participants diagnosed with specific types of kidney tumors or those who have tested negative for blood in their urine. Individuals with a history of kidney tumors, such as clear cell RCC or papillary cell RCC, may be suitable for this study. As an unphased study, this trial offers a unique opportunity to contribute to groundbreaking research that could advance future kidney cancer diagnostics.
Do I have to stop taking my current medications for the trial?
The trial information does not specify if you need to stop taking your current medications. However, it does exclude participants who have received chemotherapy drugs in the past 5 years, so you may need to discuss your specific medications with the trial team.
Why are researchers excited about this trial?
Researchers are excited about this trial because it explores new ways to detect renal tumors using methylated DNA markers. Unlike current diagnostic methods, which often rely on imaging or invasive biopsies, this approach aims to identify cancer through simple blood and urine tests. This could lead to earlier, less invasive detection, making it easier for patients to get diagnosed and start treatment sooner. Additionally, these methylated DNA markers might offer more precise insights into tumor characteristics, potentially improving personalized treatment plans.
What evidence suggests that this DNA marker is effective for identifying kidney cancer?
Research has shown that certain changes in DNA, known as DNA methylation markers, can help predict the development and outcome of kidney cancer, particularly clear cell renal cell carcinoma (ccRCC). DNA methylation affects gene function without altering the actual DNA. Studies have found that these markers can help doctors understand disease progression in patients. Using this information, doctors can better customize treatments based on likely outcomes. This method offers a promising way to manage kidney cancer more effectively. Participants in this trial will join an observational study to identify these DNA methylation markers, which may involve collecting blood, urine, and tissue samples.12345
Who Is on the Research Team?
John B. Kisiel, MD
Principal Investigator
Mayo Clinic in Rochester
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Sample Collection
Participants undergo blood, urine, and tissue sample collection for the identification of methylated DNA markers
Follow-up
Participants are monitored for safety and effectiveness after sample collection
What Are the Treatments Tested in This Trial?
Interventions
- Novel High Quality Methylated DNA Marker
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants may undergo blood, urine, and tissue sample collection on study. Participants' medical records are also reviewed.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
Citations
High-throughput methylation sequencing reveals novel ...
This study aimed to identify methylation biomarkers for RCC and establish a DNA methylation signature-based prognostic model for this disease.
High-throughput methylation sequencing reveals novel ...
This study aimed to identify methylation biomarkers for RCC and establish a DNA methylation signature-based prognostic model for this disease.
DNA methylation expression patterns predict outcome of ...
This study confirmed that DNA methylation markers can effectively predict the progression and prognosis of clear cell renal cell carcinoma (ccRCC).
Novel Expanding Renal Cell Carcinoma Biomarkers
Here we review the current state-of-the-art on RCC biomarkers, particularly focusing on the new approaches of genomics, liquid biopsy, proteomics, and ...
Update on Biomarkers in Renal Cell Carcinoma
In this review, we will discuss the current state of knowledge related to biomarkers in RCC and highlight recent and ongoing research in this area.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.